Literature DB >> 19898746

Lenalidomide stops progression of multifocal epithelioid hemangioendothelioma including intracranial disease.

Ashley Sumrall1, Ruth Fredericks, Anne Berthold, Grace Shumaker.   

Abstract

Epithelioid Hemangioendothelioma (EH) is a rare soft-tissue tumor which may present as an isolated tumor or can spread to affect internal organs. The course of EH varies, based on the tissue of origin. This case report describes a young woman who developed cutaneous EH with concurrent intracranial disease during pregnancy. After resection, the lesions returned. Even after several courses of chemotherapy and radiotherapy, the patient developed multifocal disease including pulmonary, skeletal, and liver disease. She now exhibits stable disease after approximately 6 years of therapy with lenalidomide.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19898746     DOI: 10.1007/s11060-009-0017-z

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  10 in total

1.  Thalidomide inhibits the growth and progression of hepatic epithelioid hemangioendothelioma.

Authors:  Ranjan C V Mascarenhas; Amit N Sanghvi; Lois Friedlander; Stanley J Geyer; H Scott Beasley; David H Van Thiel
Journal:  Oncology       Date:  2004       Impact factor: 2.935

2.  Aggressive intracranial and extra-cranial epithelioid hemangioendothelioma: a case report and review of the literature.

Authors:  Antonio L Fernandes; Bernardo Ratilal; Manuela Mafra; Coriolano Magalhaes
Journal:  Neuropathology       Date:  2006-06       Impact factor: 1.906

3.  [Cutaneous epithelioid hemangioendothelioma].

Authors:  S Fenniche; R Benmously; H Marrak; O Khayat; F Ben Ammar; A Debbiche; M Ben Ayed; I Mokhtar
Journal:  Ann Dermatol Venereol       Date:  2004 Aug-Sep       Impact factor: 0.777

4.  Intracranial epithelioid hemangioendothelioma: case report.

Authors:  A Puca; M Meglio; M Rollo; G F Zannoni
Journal:  Neurosurgery       Date:  1996-02       Impact factor: 4.654

Review 5.  The evolving role of lenalidomide in the treatment of hematologic malignancies.

Authors:  Efstathios Kastritis; Meletios A Dimopoulos
Journal:  Expert Opin Pharmacother       Date:  2007-03       Impact factor: 3.889

Review 6.  Lenalidomide: the emerging role of a novel targeted agent in malignancies.

Authors:  Sujith Kalmadi; Rachid Baz; Anuj Mahindra
Journal:  Drugs Today (Barc)       Date:  2007-02       Impact factor: 2.245

7.  Phase I study of lenalidomide in solid tumors.

Authors:  Antonius A Miller; Doug Case; Michele Harmon; Paul Savage; Glenn Lesser; David Hurd; Susan A Melin
Journal:  J Thorac Oncol       Date:  2007-05       Impact factor: 15.609

Review 8.  Epithelioid hemangioendothelioma with multiple site involvement. Literature review and observations.

Authors:  B K Bollinger; W B Laskin; C B Knight
Journal:  Cancer       Date:  1994-02-01       Impact factor: 6.860

9.  Epithelioid hemangioendothelioma of bone. A clinicopathologic, ultrastructural, and immunohistochemical study.

Authors:  M Tsuneyoshi; H D Dorfman; T W Bauer
Journal:  Am J Surg Pathol       Date:  1986-11       Impact factor: 6.394

10.  Phase I study to determine the safety, tolerability and immunostimulatory activity of thalidomide analogue CC-5013 in patients with metastatic malignant melanoma and other advanced cancers.

Authors:  J B Bartlett; A Michael; I A Clarke; K Dredge; S Nicholson; H Kristeleit; A Polychronis; H Pandha; G W Muller; D I Stirling; J Zeldis; A G Dalgleish
Journal:  Br J Cancer       Date:  2004-03-08       Impact factor: 7.640

  10 in total
  15 in total

Review 1.  Recurrence of Epithelioid Hemangioendothelioma during Pregnancy: Case Report and Systematic Review.

Authors:  Michael Mcculloch; Michael Russin; Arian Nachat
Journal:  Perm J       Date:  2016-07-25

2.  Freiburg Neuropathology Case Conference : A Painless Mass Lesion of the Parietal and Occipital Bones.

Authors:  C A Taschner; P Süß; F Volz; H Urbach; P Dovi-Akué; M Prinz
Journal:  Clin Neuroradiol       Date:  2018-06       Impact factor: 3.649

Review 3.  Combination capecitabine and bevacizumab in the treatment of metastatic hepatic epithelioid hemangioendothelioma.

Authors:  Augustine Lau; Steve Malangone; Myke Green; Ambuga Badari; Kathryn Clarke; Emad Elquza
Journal:  Ther Adv Med Oncol       Date:  2015-07       Impact factor: 8.168

Review 4.  Vascular sarcomas.

Authors:  Vinod Ravi; Shreyaskumar Patel
Journal:  Curr Oncol Rep       Date:  2013-08       Impact factor: 5.075

5.  Successful treatment of metastatic hepatic epithelioid hemangioendothelioma with thalidomide: a case report.

Authors:  Claire Raphael; Emma Hudson; Leslie Williams; Jason F Lester; Philip M Savage
Journal:  J Med Case Rep       Date:  2010-12-22

Review 6.  Primary intracranial epithelioid hemangioendothelioma: a low-proliferation tumor exhibiting clinically malignant behavior.

Authors:  Jian Zheng; Lingtong Liu; Junmei Wang; Shuo Wang; Yong Cao; Jizong Zhao
Journal:  J Neurooncol       Date:  2012-08-11       Impact factor: 4.130

7.  Long-term durable response to lenalidomide in a patient with hepatic epithelioid hemangioendothelioma.

Authors:  Maria Caterina Pallotti; Margherita Nannini; Claudio Agostinelli; Simona Leoni; Valerio Di Scioscio; Anna Mandrioli; Cristian Lolli; Maristella Saponara; Stefano Pileri; Luigi Bolondi; Guido Biasco; Maria Abbondanza Pantaleo
Journal:  World J Gastroenterol       Date:  2014-06-14       Impact factor: 5.742

Review 8.  Systemic treatment of soft-tissue sarcoma-gold standard and novel therapies.

Authors:  Mark Linch; Aisha B Miah; Khin Thway; Ian R Judson; Charlotte Benson
Journal:  Nat Rev Clin Oncol       Date:  2014-03-18       Impact factor: 66.675

9.  Malignant epithelioid hemangioendothelioma of the liver successfully treated with Sorafenib.

Authors:  Bruno Sangro; Mercedes Iñarrairaegui; Nerea Fernández-Ros
Journal:  Rare Tumors       Date:  2012-06-15

10.  Activity of angiogenesis inhibitors in metastatic epithelioid hemangioendothelioma: a case report.

Authors:  Sumit Gaur; Alireza Torabi; Thomas J O'Neill
Journal:  Cancer Biol Med       Date:  2012-06       Impact factor: 4.248

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.